These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 21802280)

  • 1. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutical strategies in the treatment of metastatic disease.
    Julia F; Thomas L; Dalle S
    Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
    Kirkwood JM; Moschos S; Wang W
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant systemic treatment of melanoma].
    Kähler KC; Egberts F; Hauschild A; Mohr P
    Hautarzt; 2011 Jun; 62(6):414, 416-22. PubMed ID: 21656113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
    Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
    Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
    Minutilli E; Feliciani C
    Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular-target therapy for advanced malignant melanoma].
    Takahashi S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
    Eggermont AM; Testori A; Maio M; Robert C
    Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic melanoma: the new era of targeted therapy.
    Guida M; Pisconti S; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S61-70. PubMed ID: 22443134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.